These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. LaFleur RL, Dant JC, Wasmoen TL, Callister SM, Jobe DA, Lovrich SD, Warner TF, Abdelmagid O, Schell RF. Clin Vaccine Immunol; 2009 Feb 14; 16(2):253-9. PubMed ID: 19052162 [Abstract] [Full Text] [Related]
11. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites. Gern L, Rais O, Capiau C, Hauser P, Lobet Y, Simoen E, Voet P, Pêtre J. Immunol Lett; 1994 Mar 14; 39(3):249-58. PubMed ID: 8034340 [Abstract] [Full Text] [Related]
12. Resistance to tick-borne spirochete challenge induced by Borrelia burgdorferi strains that differ in expression of outer surface proteins. Kurtti TJ, Munderloh UG, Hughes CA, Engstrom SM, Johnson RC. Infect Immun; 1996 Oct 14; 64(10):4148-53. PubMed ID: 8926082 [Abstract] [Full Text] [Related]
13. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA. Eschner AK, Mugnai K. Parasit Vectors; 2015 Feb 10; 8():92. PubMed ID: 25890386 [Abstract] [Full Text] [Related]
14. OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks. Tsao J, Barbour AG, Luke CJ, Fikrig E, Fish D. Vector Borne Zoonotic Dis; 2001 Feb 10; 1(1):65-74. PubMed ID: 12653137 [Abstract] [Full Text] [Related]
15. Human granulocytic ehrlichiosis agent infection in a pony vaccinated with a Borrelia burgdorferi recombinant OspA vaccine and challenged by exposure to naturally infected ticks. Chang YF, McDonough SP, Chang CF, Shin KS, Yen W, Divers T. Clin Diagn Lab Immunol; 2000 Jan 10; 7(1):68-71. PubMed ID: 10618280 [Abstract] [Full Text] [Related]
16. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Golde WT, Burkot TR, Piesman J, Dolan MC, Capiau C, Hauser P, Dequesne G, Lobet Y. Vaccine; 1995 Apr 10; 13(5):435-41. PubMed ID: 7639011 [Abstract] [Full Text] [Related]
17. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Luke CJ, Huebner RC, Kasmiersky V, Barbour AG. Vaccine; 1997 Apr 10; 15(6-7):739-46. PubMed ID: 9178476 [Abstract] [Full Text] [Related]
18. Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Gern L, Hu CM, Voet P, Hauser P, Lobet Y. Vaccine; 1997 Oct 10; 15(14):1551-7. PubMed ID: 9330467 [Abstract] [Full Text] [Related]
19. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine. Straubinger RK, Dharma Rao T, Davidson E, Summers BA, Jacobson RH, Frey AB. Vaccine; 2001 Oct 12; 20(1-2):181-93. PubMed ID: 11567763 [Abstract] [Full Text] [Related]
20. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. Pal U, Montgomery RR, Lusitani D, Voet P, Weynants V, Malawista SE, Lobet Y, Fikrig E. J Immunol; 2001 Jun 15; 166(12):7398-403. PubMed ID: 11390491 [Abstract] [Full Text] [Related] Page: [Next] [New Search]